DK141194B - Fremgangsmåde til fremstilling af et antiviralt complex af polykvaternære ammoniumforbindelser af dobbeltstrenget-ribonucleinsyre-polyanioner eller polyanioner af et dobbeltstrenget derivat af en dobbeltstrenget ribonucleinsyre af naturlig oprindelse. - Google Patents
Fremgangsmåde til fremstilling af et antiviralt complex af polykvaternære ammoniumforbindelser af dobbeltstrenget-ribonucleinsyre-polyanioner eller polyanioner af et dobbeltstrenget derivat af en dobbeltstrenget ribonucleinsyre af naturlig oprindelse. Download PDFInfo
- Publication number
- DK141194B DK141194B DK30375AA DK30375A DK141194B DK 141194 B DK141194 B DK 141194B DK 30375A A DK30375A A DK 30375AA DK 30375 A DK30375 A DK 30375A DK 141194 B DK141194 B DK 141194B
- Authority
- DK
- Denmark
- Prior art keywords
- double
- ribonucleic acid
- stranded
- polyanions
- stranded ribonucleic
- Prior art date
Links
- 229920002477 rna polymer Polymers 0.000 title claims description 36
- 229920000447 polyanionic polymer Polymers 0.000 title claims description 14
- 230000000840 anti-viral effect Effects 0.000 title claims description 12
- 150000003868 ammonium compounds Chemical group 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000002244 precipitate Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 238000007912 intraperitoneal administration Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 239000003792 electrolyte Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000002203 pretreatment Methods 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 229920000768 polyamine Polymers 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000228150 Penicillium chrysogenum Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 241000892910 Aspergillus foetidus Species 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000228145 Penicillium brevicompactum Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000145903 Bombyx mori cypovirus 1 Species 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB420774 | 1974-01-29 | ||
| GB420774A GB1458586A (en) | 1974-01-29 | 1974-01-29 | Antiviral complexes of double stranded rna and its derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK30375A DK30375A (is") | 1975-09-22 |
| DK141194B true DK141194B (da) | 1980-02-04 |
| DK141194C DK141194C (is") | 1980-07-21 |
Family
ID=9772754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK30375AA DK141194B (da) | 1974-01-29 | 1975-01-29 | Fremgangsmåde til fremstilling af et antiviralt complex af polykvaternære ammoniumforbindelser af dobbeltstrenget-ribonucleinsyre-polyanioner eller polyanioner af et dobbeltstrenget derivat af en dobbeltstrenget ribonucleinsyre af naturlig oprindelse. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US3978043A (is") |
| JP (1) | JPS50116620A (is") |
| BE (1) | BE824947A (is") |
| CA (1) | CA1042877A (is") |
| CH (1) | CH613118A5 (is") |
| DE (1) | DE2503442A1 (is") |
| DK (1) | DK141194B (is") |
| FR (1) | FR2258862B1 (is") |
| GB (1) | GB1458586A (is") |
| IL (1) | IL46524A (is") |
| NL (1) | NL7500955A (is") |
| SE (1) | SE400976B (is") |
| ZA (1) | ZA75540B (is") |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5998015A (ja) * | 1982-11-27 | 1984-06-06 | Microbial Chem Res Found | 免疫賦活剤 |
| US5091374A (en) * | 1987-07-17 | 1992-02-25 | Hem Research Inc. | Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3484521A (en) * | 1966-06-23 | 1969-12-16 | Int Chem & Nuclear Corp | Enhancement of memory processes in mammals with basic addition salts of ribonucleic acid |
| BR6801650D0 (pt) * | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
| BE790953A (fr) * | 1971-11-05 | 1973-05-03 | Beecham Group Ltd | Matiere biologiquement active |
-
1974
- 1974-01-29 GB GB420774A patent/GB1458586A/en not_active Expired
-
1975
- 1975-01-27 US US05/544,211 patent/US3978043A/en not_active Expired - Lifetime
- 1975-01-27 SE SE7500854A patent/SE400976B/xx unknown
- 1975-01-27 ZA ZA00750540A patent/ZA75540B/xx unknown
- 1975-01-28 CA CA218,867A patent/CA1042877A/en not_active Expired
- 1975-01-28 DE DE19752503442 patent/DE2503442A1/de not_active Withdrawn
- 1975-01-28 NL NL7500955A patent/NL7500955A/xx not_active Application Discontinuation
- 1975-01-29 IL IL46524A patent/IL46524A/xx unknown
- 1975-01-29 JP JP50012299A patent/JPS50116620A/ja active Pending
- 1975-01-29 BE BE152853A patent/BE824947A/xx unknown
- 1975-01-29 FR FR7502721A patent/FR2258862B1/fr not_active Expired
- 1975-01-29 DK DK30375AA patent/DK141194B/da unknown
- 1975-01-29 CH CH102875A patent/CH613118A5/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7770075A (en) | 1976-07-29 |
| CA1042877A (en) | 1978-11-21 |
| IL46524A (en) | 1978-10-31 |
| BE824947A (fr) | 1975-07-29 |
| SE7500854L (is") | 1975-07-30 |
| DK30375A (is") | 1975-09-22 |
| GB1458586A (en) | 1976-12-15 |
| IL46524A0 (en) | 1975-05-22 |
| SE400976B (sv) | 1978-04-17 |
| CH613118A5 (is") | 1979-09-14 |
| NL7500955A (nl) | 1975-07-31 |
| FR2258862B1 (is") | 1980-02-08 |
| FR2258862A1 (is") | 1975-08-22 |
| DK141194C (is") | 1980-07-21 |
| JPS50116620A (is") | 1975-09-12 |
| DE2503442A1 (de) | 1975-07-31 |
| US3978043A (en) | 1976-08-31 |
| ZA75540B (en) | 1976-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0428716B2 (is") | ||
| JPH07504928A (ja) | 高分子グルクロン酸化合物，その製造方法及び用途，特にゲル化剤，粘度付与剤，湿気付与剤，安定剤，キレート化剤又は凝集剤としての用途 | |
| JPS63316730A (ja) | 抗ウイルス剤 | |
| US3845033A (en) | Complexes of double-stranded ribonucleic acid with polyquaternary amine | |
| FI72143C (fi) | Foerfarande foer framstaellning av maenniskointerferon. | |
| DK141194B (da) | Fremgangsmåde til fremstilling af et antiviralt complex af polykvaternære ammoniumforbindelser af dobbeltstrenget-ribonucleinsyre-polyanioner eller polyanioner af et dobbeltstrenget derivat af en dobbeltstrenget ribonucleinsyre af naturlig oprindelse. | |
| FI69868C (fi) | Foerfarande foer enzymatisk framstaellning av ett dubbelstraengat rna anvaendbart som if-inducerare | |
| CN101362805A (zh) | 黄芪多糖的提取和分子修饰方法 | |
| EP3145495A1 (en) | Coating method and materials | |
| EP0692475A4 (en) | N-METHYLE-N - / - g (a), - g (D) -GLUCOPYRANOZIL / AMMONIAC-2- / ACRIDON-9-ON-10-YLE / ACETATE / CYCLOPHERONE PROVIDED WITH INTERFERON PRODUCTION PROPERTIES, ANTIVIRALS ( (INCLUDING ANTI-HIV ACTIVITY), PEST CONTROL, ANTI-PROMOTER AND RADIATION PROTECTORS | |
| CA1339111C (en) | Antiviral agent | |
| US4018916A (en) | Antiviral ionic complexes of double-standard RNA | |
| EA018111B1 (ru) | Конъюгаты белок-полимер и способ лечения инфекции вируса гепатита c или гепатита b | |
| SU1678206A3 (ru) | Способ получени 1, 3, 4-тиадиазол-2-цианамида или его фармацевтически приемлемых солей | |
| JPH0899986A (ja) | ガングリオシドの製造法 | |
| EP1338281A1 (en) | Method for producing an immunotropic antiviral preparation | |
| CN116135908B (zh) | 一种锍盐修饰的聚乙烯亚胺及其制备方法和基因载体的用途 | |
| US2645637A (en) | Synthesis of adenosine-5'-triphosphate | |
| JP2001503752A (ja) | 新規クネベナゲル縮合生成物、その製法及びその使用 | |
| WO2002056889A1 (en) | Method of synthesis of chromium amino acid nicotinate complex | |
| SE443088B (sv) | Forfarande for framstellning av sekretin genom extraktion av tunntarm | |
| Severin et al. | Hydrophobized antiviral antibodies and antisense oligonucleotides | |
| CN103189354A (zh) | 具有抗病毒功效的1,4-二氢吡啶衍生物 | |
| JPS62142122A (ja) | ＨＢｓＡｇ複合体、その製造法およびＨＢワクチン | |
| JPS6075431A (ja) | エリスロマイシンの塩およびそれを有効成分とする抗生−免疫賦活剤 |